Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Large Blend · Tortoise

Patient Opportunity Trust Class IS (MVISX)

Ticker MVISX · Since 2018-08-22 · · Holdings as of Jun 30, 2026

Expense ratio
1.33%$133/yr per $10k
5-yr return
+7.1%annualized
1-yr return
+27.8%as of Dec 2025
Net assets
$2.0Ball share classes
Holdings
38

Bottom line

Is MVISX a good fund? The bottom line

MVISX is the Class IS share class of Patient Opportunity Trust, an actively managed large blend mutual fund from Tortoise.

Annual fees run 1.33% — about $133 a year on every $10,000 invested, more expensive than 78% of large blend funds we track.

It returned +27.8% over one year, +7.1% a year over five years (as of Dec 31, 2025, per its prospectus).

With $2.0 billion in net assets and 38 holdings, its largest position is Royalty Pharma PLC (7.0%) and the top 10 make up 54.8% of the portfolio.

What stands out

  • No front-end sales load

What to watch

  • Expensive for its category (1.33%)
  • Concentrated: top 10 holdings are 54.8% of assets

Updated Nov 19, 2026

What MVISX invests in

The Patient Opportunity Trust (the Fund) seeks long term growth of capital.

"The Fund normally makes investments that, in the portfolio managers opinion, offer the opportunity for long-term growth of capital. The portfolio managers exercise a flexible strategy in the selection of investments, not limited by investment style or asset class. The investment strategy typically involves identifying instances where the Advisor believes the capital markets have mispriced investment opportunities and exploiting price discrepancies and inefficiencies in the market. The Fund may invest without limit in the common stock of U.S. and foreign issuers (including securities denominated in foreign currencies) of all sizes and in other U.S. and foreign securities, including emerging markets, and including: securities convertible into common stock; securities issued through private placements; preferred securities; warrants and rights; securities issued by investment companies…

From the fund's prospectus (filed Apr 30, 2026).

MVISX performance

Average annual total returns
1 yr5 yr10 yr
MVISX+27.8%+7.1%—
Large Blend median+13.8%+9.7%+10.9%

Source: Fund prospectus, as of Dec 31, 2025

Full MVISX performance history →

What MVISX costs

On a $10,000 investment, MVISX's 1.33% expense ratio costs about $133 a year. The prospectus estimates $1,591 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.

See the full MVISX fee table →

MVISX top 10 holdings

#Holding% of fund
1Royalty Pharma PLC RPRX6.98%
2Citigroup Inc C6.97%
3Alphabet Inc GOOGL6.67%
4UnitedHealth Group Inc UNH6.21%
5Amazon.com Inc AMZN5.64%
6NVIDIA Corp NVDA4.98%
7CVS Health Corp CVS4.51%
8QXO Inc QXO4.48%
9Norwegian Cruise Line Holdings NCLH4.21%
10Precigen Warrant Restricted4.19%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 54.8% of the fund. See all top 25 holdings and asset mix →

Alternatives to MVISX

More funds like MVISX →

MVISX FAQ

What is the expense ratio of MVISX?
MVISX's expense ratio is 1.33%, which works out to about $133 a year for every $10,000 invested. The prospectus estimates total costs of $1,591 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is MVISX a good investment?
It depends on your goals, but the data points to: no front-end sales load; expensive for its category (1.33%); concentrated: top 10 holdings are 54.8% of assets. This is general information, not personalized advice.
What does MVISX hold?
MVISX's largest holdings are Royalty Pharma PLC (7.0%), Citigroup Inc (7.0%), Alphabet Inc (6.7%), UnitedHealth Group Inc (6.2%), Amazon.com Inc (5.6%). It holds 38 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is MVISX's 5-year return?
MVISX returned +7.1% a year over the five years ending Dec 31, 2025. Past performance does not guarantee future results.
Does MVISX have a sales load?
No. MVISX has no front-end sales charge.
Who manages MVISX?
MVISX is offered by Tortoise through Advisor Managed Portfolios.